Sportoletti Paolo
Hematology and Clinical Immunology Section, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy.
Pediatr Rep. 2011 Jun 22;3 Suppl 2(Suppl 2):e6. doi: 10.4081/pr.2011.s2.e6.
NPM1 is the most frequently mutated gene in AML and the role of the NPM1 mutant in acute myeloid leukemia along with its leukemogenic potential are still under investigation.NPM1 genetic alterations can contribute to leukemogenesis through the direct oncogenic effect of the mutant protein and the concomitant loss of one functional allele. Npm1 loss determines tumor development in the mouse while in human NPM1 maps in a chromosomal region frequently loss in myelodysplastic syndrome (MDS). The NPM1 mutant cytoplasmic delocalization in leukemic blasts alters multiple cellular pathways through either loss or gain of function effects on different protein partners.Here we discuss the most relevant studies on the role of the NPM1 molecule in hematological malignancies and both in vitro and in vivo studies that are trying to elucidate the way by which the NPM1 mutation induces leukemia.
NPM1是急性髓系白血病(AML)中最常发生突变的基因,NPM1突变体在急性髓系白血病中的作用及其致白血病潜能仍在研究中。NPM1基因改变可通过突变蛋白的直接致癌作用以及一个功能等位基因的伴随缺失导致白血病发生。Npm1缺失决定了小鼠体内肿瘤的发展,而在人类中,NPM1定位于骨髓增生异常综合征(MDS)中经常缺失的染色体区域。白血病母细胞中NPM1突变体的细胞质异位通过对不同蛋白质伴侣的功能丧失或获得效应改变多种细胞途径。在此,我们讨论关于NPM1分子在血液系统恶性肿瘤中的作用的最相关研究,以及试图阐明NPM1突变诱导白血病方式的体外和体内研究。